Hoe zit het met standaardiseren van testen?
Geplaatst: Za 08 Jan 2022, 23:14
https://pubmed.ncbi.nlm.nih.gov/2183731/
Also, standards have not yet been developed for PCR testing and there is a risk of false-positive test results.
https://www.uofmhealth.org/health-library/hw5113
============================================================================
The utility of serologic test results in arriving at a diagnosis is limited by the inherent deficiencies of the existing tests regarding sensitivity and specificity.
The lack of test standardization further complicates the interpretation of test results.
A proficiency testing program for Lyme disease serology conducted among 45 laboratories indicated a high rate of false-negative results and a considerable rate of false-positive results.1
Most alarming, however, was the variability of results, both among different laboratories and within a given laboratory.
The reproducibility of test results was poor
https://journals.sagepub.com/doi/pdf/10 ... 9600800209
'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
https://www.jhsph.edu/research/centers- ... esting.pdf
Educatie research centrum van Johns Hopkins instituut
J. Stephen Dumler, M.D.Division of Medical MicrobiologyDepartment of PathologyThe Johns Hopkins University School of Medicine:
Laboratory Diagnosis of Lyme disease
Serology
Enzyme immunoassay (EIA) methods
very sensitive, limited specificity (false positives)
whole bacterial cell lysates or individual recombinant proteins
generally not immunoglobulin class specific
Western blot assays to aid specificity
supplemental method for EIA positives requires presence of specific antigen bands on IgM or IgG immunoblots
Pitfalls in serologic diagnosis
lack of early response
abrogation by early Rx
persistent antibody in absence of active disease
lack of standardization
no FDA-cleared test for detection of CSF antibodies
Wormser zegt het ook:
One of the limitations of ELISA for detection of B. burgdorferi sensu lato antibodies is lack of standardization. Variations exist between assays in terms of antigenic composition
and in the detection of specific immunoglobulin classes, particularly in the detection of IgM antibodies (7, 8, 34, 167, 337)
https://www.aldf.com/wp-content/uploads ... enfeld.pdf
Also, standards have not yet been developed for PCR testing and there is a risk of false-positive test results.
https://www.uofmhealth.org/health-library/hw5113
============================================================================
The utility of serologic test results in arriving at a diagnosis is limited by the inherent deficiencies of the existing tests regarding sensitivity and specificity.
The lack of test standardization further complicates the interpretation of test results.
A proficiency testing program for Lyme disease serology conducted among 45 laboratories indicated a high rate of false-negative results and a considerable rate of false-positive results.1
Most alarming, however, was the variability of results, both among different laboratories and within a given laboratory.
The reproducibility of test results was poor
https://journals.sagepub.com/doi/pdf/10 ... 9600800209
'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
https://www.jhsph.edu/research/centers- ... esting.pdf
Educatie research centrum van Johns Hopkins instituut
J. Stephen Dumler, M.D.Division of Medical MicrobiologyDepartment of PathologyThe Johns Hopkins University School of Medicine:
Laboratory Diagnosis of Lyme disease
Serology
Enzyme immunoassay (EIA) methods
very sensitive, limited specificity (false positives)
whole bacterial cell lysates or individual recombinant proteins
generally not immunoglobulin class specific
Western blot assays to aid specificity
supplemental method for EIA positives requires presence of specific antigen bands on IgM or IgG immunoblots
Pitfalls in serologic diagnosis
lack of early response
abrogation by early Rx
persistent antibody in absence of active disease
lack of standardization
no FDA-cleared test for detection of CSF antibodies
Wormser zegt het ook:
One of the limitations of ELISA for detection of B. burgdorferi sensu lato antibodies is lack of standardization. Variations exist between assays in terms of antigenic composition
and in the detection of specific immunoglobulin classes, particularly in the detection of IgM antibodies (7, 8, 34, 167, 337)
https://www.aldf.com/wp-content/uploads ... enfeld.pdf